Big Law

Zogenix acquires Modis Therapeutics for up to $400M

Zogenix has agreed to acquire privately-held Oakland, CA-based Modis Therapeutics, a developer of therapies for rare inherited diseases. The lead candidate is MT1621 for the treatment of thymidine kinase 2 deficiency, an inherited mitochondrial DNA depletion disorder that is frequently fatal.

Read More from Source

    Leave a Review or Comment

    Your email address will not be published. Required fields are marked *

    Back to top button